Bi-Huei Yang

Bi-Huei Yang is a Principal Scientist in Cancer Immunotherapy at Fate Therapeutics Inc., with extensive experience in T cell engineering and immunotherapy. At Fate Therapeutics, Bi-Huei Yang has led projects involving the combination of TCR and CAR technologies to address antigen escape, and has supervised the development of next-gen iPSC-derived T cell platforms, contributing to the IND filing for FT819. Prior to this role, Bi-Huei Yang served as a Postdoctoral Research Fellow at the University of California San Diego, focusing on Treg transcriptional networks and macrophage roles in beta-cell proliferation, resulting in publications in prestigious journals. Educational background includes a Ph.D. in Molecular Medicine from Medizinische Hochschule Hannover and advanced degrees in Clinical Laboratory Sciences and Medical Biotechnology from National Taiwan University.